Key Actionable Driver Mutations in Patients with Advanced NSCLC 

This enduring material from our fifth videoconference on advanced NSCLC for pathologists and laboratory professionals will consist of a 20-minute didactic presentation by a subject matter expert on key actionable driver mutations in patients with advanced NSCLC. In the remaining 40 minutes, two participants will present and share real-world cases and challenges from their institutions and seek feedback from participants and subject matter experts. The session will provide knowledge and best practices related to key actionable driver mutations in patients with advanced NSCLC and guidance on real-life challenges they may face in their institutions. 

The videoconferences in this series utilize the Project ECHO® approach, leveraging technology to provide access to scarce resources, help participants master complex topics through case-based learning, facilitate peer-to-peer sharing of best practices to improve knowledge and outcomes, reduce peer isolation, and foster professional development. 

This is an online course.  If you attended the live event please claim credit Here 

The activity offers 1.0 CME/CMLE credit. 

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. 

Faculty/Authors

Dr. Diana Ionescu, MD, FRCPC, FCAP
Consultant Pathologist at BC Cancer Agency
Clinical Professor, UBC
The University of British Columbia
Department of Pathology and Laboratory Medicine
Vancouver, BC Canada  

VOLUNTEER CONTRIBUTORS:

Brandon Sheffield, MD, FRCPC
Medical Director of Immunohistochemistry and Molecular Pathology
Physician Lead of Research
William Osler Health System
Brampton, ON  Canada 

Physician's Competency: Patient care, Medical knowledge, Interpersonal and Communication Skills, Professionalism   

CME/CMLE Credit: 1.0
Estimated Completion Time: 1.0 hour
Format: Online educational activity

Credit Designation Statement

To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line. 

Funded by independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer, Inc. 

Instructions

To claim CME/CMLE credit for the exercise, do the following:

1. Review the Technical Considerations.
2. Click Go to Content and click the first module of the course.
3. Complete the Demographic Survey.
4. Review the Educational Activity.
5. Submit the Post-Activity Survey.
6. Submit the course Evaluation.
7. Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Upon completion of this activity, you will be able to:

• Discuss key actionable driver mutations in patients with advanced NSCLC (eg, EGFR, ALK, ROS1, BRAF) 

• Develop and apply effective testing algorithms for patients with advanced NSCLC to ensure appropriate testing for key actionable driver mutations (eg, EGFR, ALK, ROS1, BRAF) 

• Emphasize the role of the pathologist in the multidisciplinary lung cancer team